Share on LinkedInShare on LinkedIn

ARTICLE · 12 JUNE 2024

EU Pharmaceutical Package - EU Pharmaceutical Legislative Reform And Its Impact On Türkiye

Gün + Partners
Gün + Partners
Contributor
Gün + Partners

Gün + Partners

We are one of the oldest and largest law firms in Turkey and are considered internationally to be...

View firm profile
Explore more from Gün + Partners

On 26 April 2023, the European Commission (the "Commission") adopted a proposal for a new Directive and Regulation (the "Proposal") which revise and replace...

European UnionIntellectual Property

On 26 April 2023, the European Commission (the “Commission”) adopted a proposal for a new Directive and Regulation (the “Proposal”) which revise and replace the existing general pharmaceutical legislation.

The proposal adopted by the Commission replaces the existing general pharmaceutical legislation (Regulation 726/2004 and Directive 2001/83/EC) and the legislation on pharmaceuticals for children and rare diseases (Regulation 1901/2006 and Regulation 141/2000/EC respectively).

In the Commission's press release on the Proposal, it was stated that the pharmaceuticals authorized in the EU are still not reaching patients fast enough and are not equally accessible across all Member States. The proposal aims to prevent pharmaceutical shortages and unmet medical needs due to high pricing of innovative treatments. In addition to addressing public health from a pharmaceutical access viewpoint, the proposal aims to adapt the rules to new technologies, reduce bureaucracy,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from